Compositions and methods for treating the eye

Patent metadata

Field	Value
Publication number	US-11878041-B2
Application number	US-202117515882-A
Country	US
Kind code	B2
Filing date	Nov 1, 2021
Priority date	Jul 27, 2018
Publication date	Jan 23, 2024
Grant date	Jan 23, 2024

Abstract

The present invention relates to compositions comprising one or more compounds and/or extracts which induce, promote and/or improve production/release/delivery/excretion of hyaluronic acid from and/or in the cornea, and methods of using the compositions to treat the eye.

First claim

What is claimed is:

1. A method for treating a patient having decreased or low-level production, release, delivery, and/or excretion of hyaluronic acid from and/or in the cornea comprising the step of topically administering to the eye of the patient an ophthalmologic composition comprising:
i) a safe and effective amount of one or more extracts of Pichia anomala to achieve a Pichia anomala extract concentration in the corneal fluid in the corneal tissues of the eye of at least about 0.3 mg/ml, wherein the Pichia anomala extract is characterized as having:
a) a solids content of between 26 and 40 g/l,
b) a pH between 6.0 and 7.0,
c) a protein content between 4 and 90 g/l, and
d) a sugars content ranging between 18 and 29 g/l;

ii) a safe and effective amount of a permeation enhancer; and
iii) an ophthalmologically acceptable carrier.

2. The method of claim 1 , wherein the Pichia anomala extract in the composition comprises oligosaccharides and polysaccharides having a weight average molecular weight of from about 180 to about 800,000 Da.

3. The method of claim 1 , wherein the Pichia anomala extract in the composition comprises oligosaccharides and polysaccharides having an average degree of polymerization of from DP 1 to DP 4444.

4. The method according to claim 1 , wherein the permeation enhancer is present at a concentration of from about 0.01% to about 20% (w/v) of the total composition.

5. The method of claim 4 , wherein the permeation enhancer is present at a concentration of from about 0.1% to 10% (w/v) of the total composition.

6. The method of claim 5 , wherein the permeation enhancer is present at a concentration of from about 0.25% to 5% (w/v) of the total composition.

7. The method of claim 1 , wherein the permeation enhancer is selected from the group consisting of polyoxyethylene, polyoxyethylene ethers of fatty acids, sorbitan monooleate, sorbitan monolaurate, polyoxyethylene monolaurate, polyoxyethylene sorbitan monolaurate, fusidic, acid, EDTA, disodium EDTA, cholic acid, deoxycholic acid, glycocholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium cholate, sodium glycocholate, glycocholate, sodium deoxycholate, sodium taurocholate, sodium glycodeoxycholate, sodium taurodeoxycholate, chenodeoxycholic acid, urosdeoxycholic acid, saponins, glycyrrhizic acid, ammonium glycyrrhizide, decamethonium, decamethonium bromide, and dodecyltrimethylammonium bromide, or a mixture of two of any of the above.

8. The method according to claim 2 , wherein the permeation enhancer is present at a concentration of from about 0.01% to about 20% (w/v) of the total composition.

Assignees

• Johnson & Johnson Surgical Vision Inc

Inventors

• Li Wen-Hwa Ting
• Mahmood Khalid
• Parsa Ramine
• Randhawa Manpreet
• Bai Mingqi
• Holeva Kenneth T

Classifications

• A61K36/064 Primary

  Saccharomycetales, e.g. baker's yeast · CPC title

• A61K9/0048 Primary

  Eye, e.g. artificial tears · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• A61K47/38

  Cellulose; Derivatives thereof · CPC title

• A61P27/04

  Artificial tears; Irrigation solutions · CPC title